You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Bioimpedance based Intracranial Mapping for Monitoring Evolving TBI

    SBC: RYTEK MEDICAL INC            Topic: 105

    ABSTRACT Approximately million individuals suffer from traumatic brain injury TBI annually with over expected to die as a result of their injury In these most severe cases patients are typically admitted to the intensive care unit ICU for continuous monitoring and treatment of their injury Standard monitoring includes implantation of an intracranial pressure ICP sensor arterial ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  2. Design and Development of Immunotolerant S. aureus Biotherapies

    SBC: Lyticon LLC            Topic: R

    The increasing incidence of multi drug resistance in Staphylococcus aureus and other bacteria represents a public health crisisTwo thirds of hospital associated Saureus infections andof those acquired in the community are now methicillin resistantMRSAMRSA causes rtinfections in the US each yearand it is responsible for half of all US deaths caused by drug resistant bacteriaThis threat to public he ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  3. Preclinical Development of a Novel Small Molecule Drug for Sepsis

    SBC: THERASOURCE, LLC            Topic: 300

    PROJECT DESCRIPTIONThis STTR Phase I proposal is intended to demonstrate the feasibility of developing tanshinone small molecule analogTSAas an effective and safe small molecule therapy for patients with sepsis and septic shockIn the USmore than one million people develop sepsis every yearYetno effective anti sepsis treatment exists other than antibiotics and supportive careWe have discovered that ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  4. Science Take-Out Kits for Environmental Health Education

    SBC: Science Take-Out, LLC            Topic: NIEHS

    ABSTRACT Nearlypercent of death and diseaseworldwideis linked to environmental factorsWHOthereforeit is critical that the general public has a basic understanding of how the environment affects their health and how they might protect themselves against environmental exposuresUnfortunatelyenvironmental health is typically covered minimallyif at allin secondary school classroomsMartinaand there are ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  5. Discovery of Novel Drugs for Autism

    SBC: ASDDR, LLC            Topic: 101

    Summary The goal of this study is to discover novelmechanism based pharmacological intervention for autisma devastating neurodevelopmental disorder with no treatment currentlyGenetic sequencing has revealed extensive overlap in risk genes for autism and for cancermany of which are chromatin remodeling factors important for transcriptional regulationsuggesting the possibility of repurposing the ant ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  6. Polo box PLK Inhibitors Target Tumors Resistant to ATP Competitive Compounds

    SBC: PPI PHARMACEUTICALS, LLC            Topic: NCI

    Polo like kinase PLK is a central player in regulating entry into and progression through mitosis Many studies have validated PLK as an anti tumor drug target and its inhibition is potently anti proliferative to cancer cells However recent data suggests that there are two major disadvantages of the conventional approach to blocking the kinase activity of PLK First both general kinome ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  7. A Novel Scaffold to Promote Skin Regeneration

    SBC: FirstString Research, Inc            Topic: NIAMS

    PROJECT SUMMARY Dermal scarring affects more than million people worldwide annually over million people are injured in motor vehicle accidents over million patients are severely burned and thousands of warriors are wounded in military blasts In severe burns more than of patients develop hypertrophic scar contraction which leads to hypertrophic scar contractures HSc HSc a ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  8. Novel Inhibitors of PSMB and PSMB for the Treatment of Multiple Myeloma

    SBC: InhiProt            Topic: 103

    Multiple myeloma is incurable hematologic malignancy with an expected median survival of years The proteasome inhibitors bortezomib carfilzomib and the recently approved ixazomib are a mainstay of current myeloma treatment Despite an initial response rate approaching to proteasome inhibitor containing combinations all patients relapse and eventually become resistant to any treatments ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  9. A novel product for tendinopathy treatment

    SBC: NEW YORK R & D CENTER FOR TRANSLATIONAL MEDICINE & THERAPEUTICS INC            Topic: NIA

    Project Summary This study aims to prove the concept and feasibility that TendonCure extracellular vesicles that contain signaling molecules i e exosomes secreted by mesenchymal stem cells i e tendon stem progenitor cells TSPCs or adipose derived stem cells ADSCs from individual patients donors cultured on a novel scaffold exert therapeutic efficacy on tendinopathy when injected into ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  10. Therapeutic antibodies for treatment of hantavirus cardiopulmonary syndrome

    SBC: CELDARA MEDICAL, LLC            Topic: R

    Project Summary Rodent borne viral outbreaks are increasing in both frequency and impactAs weather patterns evolverodent populations are affected and may multiply in areas where increased contact with humans results in infectionHantavirusesincluding AndesANDVand Sin NombreSNVare transmitted through the excreta of infected rodents andwhen aerosolizedinfect humansIn the Americashantavirus infection ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government